In multiple myeloma (MM), p53 is frequently dysregulated culminating in abnormal function of p53 signaling pathway and its related downstream targets [1], while mutations or deletions in TP53 gene are rare phenomena in MM, with approximate rates of 3 or 10%, respectively, at diagnosis as reported by us and others [2–5]. The gene discussed is TP53; the disease is plasma cell myeloma.